Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

REMAP-CAP sarilumab, 2021
RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
48/402 conclusif
  • demonstrated 76 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
28/28 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).